k22

BN80933 is a dual inhibitor of lipid peroxidation and neuronal nitric oxide synthase; Neuroprotectant.

ZIKV-IN-K22 is a potent antiviral agent against a broad range of coronaviruses by targeting membrane-bound viral RNA replication, effectively inhibiting ZIKV with IC50 of 2.1 μM.

GSK2292767 is a potent and selective inhibitor of PI3Kδ.

GSK2292767 FA is a potent and selective inhibitor of PI3Kδ (pIC50 : 10.1).GSK2292767 FA is more than 500-fold more selective than other PI3K isoforms.GSK2292767 FA can be used in the study of respiratory diseases.

GSK2256098 (GTPL7939) is a small molecule FAK kinase inhibitor.

GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign.

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

GSK2256294A (GSK 2256294) is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.

GSK2263167 is an agonist of S1P1 receptor.

GSK2239633 is a potent CC-chemokine receptor 4 antagonist with pIC50 of 7.9. The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.

GSK2210875 is a mGluR5 antagonist with oral activity.

M4K2234 (compound 26b), an ALK2 inhibitor, demonstrates selective inhibition of ALK2 and ALK5 with IC50 values of 5 nM and 2144 nM, respectively. Serving as a chemical probe for ALK1 and ALK2 protein kinases, M4K2234 holds potential for cancer research applications [1].

Anti-MouseRANKL CD254Antibody (IK22 5) is a rat-derived IgG2a, κ antibody inhibitor targeting the mouse RANKL CD254.

Adenosine 5'-methylenediphosphate (sodium salt) is also referred to as an inhibitor of ecto-5'-nucleotidase.

GSK223 is an iE-DAP-stimulated IL-8 release inhibitor via the NOD1 signaling pathway.

GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.

M4K2281 is a potent and selective inhibitor of ALK2 with a half-maximal inhibitory concentration (IC50) of 2 nanomolar. In both biochemical and cellular assays, M4K2281 and M4K2308 demonstrate strong efficacy against ALK2. Moreover, M4K2281 exhibits a brain-to-plasma ratio that ranges from moderate to high.